PAREXEL Intl Corp.
PRXL
NASDAQ88.08
USD
-0.02
- -
CIK
0000799729
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- IPO Date
- Nov 22, 1995
- CIK
- 0000799729
- Similar Companies
- Business
- PAREXEL International Corporation (PRXL) is a leading global contract research organization (CRO) that provides comprehensive biopharmaceutical services, including Phase I to IV clinical trials management; regulatory consulting and approval support; medical communications; market access strategies; drug safety and pharmacovigilance; data management and biostatistics; commercialization services; and real-world evidence generation. The company offers expertise across therapeutic areas such as oncology, neuroscience, infectious diseases, immunology, cell and gene therapy, and rare diseases, serving pharmaceutical, biotechnology, and medical device clients worldwide through a workforce of approximately 24,000 employees operating in over 100 countries. Founded in 1982 and headquartered in Raleigh, North Carolina, with significant operations in North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, PAREXEL supports drug development from early-phase innovation to post-market surveillance using advanced technologies like AI-driven solutions for case processing, literature surveillance, and analytics. In recent developments, PAREXEL established a key collaboration with Palantir Technologies in 2024 to enhance AI-powered data management in clinical trials; the company was acquired by EQT and Goldman Sachs in November 2021 for $8.5 billion following its prior purchase by Pamplona Capital Management in 2017; and it continues to drive innovations in decentralized trials, patient diversity, and functional service provision amid a robust pipeline of awards expected to accelerate revenue growth into 2026.
Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research®